Genolimzumab

Hutchison China MediTech Limited announces its unaudited financial results for the six months ended June 30, 2019 and provides updates on key clinical programs. London: Tuesday, July 30, 2019: Hutchison China MediTech Limited (“ Chi-Med ”) (AIM/Nasdaq: HCM) today announces its unaudited financial results for the six months ended June 30, 2019 and provides updates on key clinical programs. Major highlights include: Positive surufatinib China Phase III study in non-pancreatic neuroendocrine tumors (“NET”) – Interim analysis of SANET-ep study confirmed to have met primary endpoint and the Independent Data Monitoring Committee (“IDMC”) recommended the study be un-blinded, a year ahead of schedule. New Drug Application (“NDA”) is now being prepared for submission during 2019; Early progress on Elunate ® (fruquintinib capsules) with China in-market sales in colorectal cancer (“CRC”) of $11.4 million 1 (RMB77.1 million) during H1 2019; Discussions in progress for potential inclusion in the China National Reimbursement Drug List (“NRDL”) at the next update in Q4 2019; Potential for first savolitinib NDA targeted for H1 2020 – for MET 2 Exon 14 deletion non-small cell lung cancer (“NSCLC”) in China. Oral presentations of savolitinib data made at scientific conferences in H1 2019 in lung cancer (monotherapy and combination with Tagrisso ® ) and kidney cancer (combination with Imfinzi ® ). Video webcast presentation at 9:00 a.m. BST and additional conference call at 9:00 a.m. EDT. “Chi-Med’s business is progressing well on all fronts.” said Simon To, Chairman, Chi-Med. “All major clinical readouts in the first half were encouraging, with the stand-out results being surufatinib’s positive Phase III outcome in non-pancreatic NET and savolitinib’s preliminary data in MET Exon 14 deletion NSCLC along with the completion of enrollment of its registration study. We believe these accomplishments have the potential to support Chi-Med’s next two NDA submissions, surufatinib later this year and savolitinib early next year.” “Highly encouraging preliminary data was also reported for the savolitinib / Tagrisso ® combination in NSCLC, which led to the initiation of a global registration intent trial by AstraZeneca AB (publ) (“AstraZeneca”), the SAVANNAH study, early this year. Also, recently released preliminary data for the savolitinib / Imfinzi ® combination in kidney cancer is promising.” “Our first approved oncology drug, Elunate ® , is making progress, with first six-month revenue well ahead, at the same stage, of the five small molecule VEGFR 3 inhibitors previously launched by multinational companies in China. In our view, with time and inclusion in the China NRDL, Elunate ®’ s well documented efficacy and safety pro make it a formidable competitor.” “Business is as usual for our Commercial Platform, which generated 9% net income growth on a CER 4 basis versus same period last year. This income helps significantly to fund our clinical development programs as well as our discovery engine which produced yet another exciting oncology asset, our ninth, with the IND 5 submission of our novel IDH 1/2 inhibitor 6 HMPL-306.” “Our organization is expanding rapidly, with our New Jersey-based international clinical and regulatory team scaling up to manage global registration studies on surufatinib and fruquintinib and early development on our B-cell malignancy assets. Our in-house oncology commercial team in China is also growing fast, managing medical affairs and getting ready for the potential launch of surufatinib late next year.” “Looking ahead at the next two years, we expect to accelerate our transformation into a fully integrated and globally-facing biopharmaceutical company with capability to discover, develop and launch multiple novel drug innovations aimed at addressing a broad range of unmet medical needs and benefiting a large number of patients.” Financial Highlights The items below are selected financial data for the six months ended June 30, 2019. All monetary figures are expressed in U.S. dollars unless otherwise stated. For more details, please refer to “Financial Review”, “Operations Review” and “Interim Unaudited Condensed Consolidated Financial Statements” below. OVERALL GROUP: sufficient resources to reach multiple value inflection points on our pipeline Group r evenue $102.2 million (H1-18: $102.2m). N et loss attributable to Chi‑Med of $45.4 million (H1-18: net loss of $32.7m). Adjusted Group net cash flows (non-GAAP) was -$63.7 million in H1 2019 including the repayment of a total of $26.9 million in bank loans, leaving the Group with no outstanding bank borrowings. Cash from our Commercial Platform, as well as payments received from our multinational partners, continued to offset a material part of our research and development (“R&D”) expenses. · Cash resources of $383.6 million at Group level as of June 30, 2019 (December 31, 2018: $420.3m), including cash, cash equivalents and short-term investments of $237.3 million (December 31, 2018: $301.0m) and unutilized bank facilities of $146.3 million (December 31, 2018: $119.3m). I NNOVATION PLATFORM : increased investment in R&D driven by expansion of our organization, operations and progress on our clinical development pipeline Consolidated revenue was $ 12.0 million (H1-18: $13.6m) mainly due to payments from AstraZeneca and Lilly. During H1 2019, following the launch of Elunate ® in late 2018, we recorded $5.5 million (H1-18: $1.1m) in manufacturing and service fee revenues as well as royalty income from Lilly. R&D expenses on an as adjusted (non-GAAP) basis increased to $74.5 million (H1-18: $66.7m), primarily driven by the progress in the development of our eight clinical drug candidates, five of which are either in or about to start development outside China; the ramp-up of our small molecule manufacturing operations in Suzhou; expansion of U.S. and international clinical and regulatory operations; and establishment of our oncology commercial infrastructure in China. · Net loss from our Innovation Platform attributable to Chi-Med of $63.8 million (H1-18: net loss of $52.9m). COMMERCIAL PLATFORM: solid net income growth on a CER basis due to continued progress in our Prescription Drugs business Total consolidated sales grew 2% (7% at CER) to $90.2 million (H1-18: $88.6m) mainly due to progress on our Prescription Drugs subsidiary Hutchison Sinopharm 7 being partially offset by rationalization of certain low contribution products in the Consumer Health business. Total sales of non-consolidated joint ventures increased 2% (8% at CER) to $276.9 million (H1-18: $271.7m) driven by solid performance on our leading prescription cardiovascular drug, She Xiang Bao Xin (“SXBX”) pill, which grew 9% (15% at CER) to $141.0 million (H1-18: $129.8m). Total consolidated net income from our Commercial Platform attributable to Chi-Med increased 3% (9% at CER) to $27.7 million (H1-18: $26.9m). --- U.K. Analysts Meeting and Webcast Scheduled Today at 9:00 a.m. BST (4:00 p.m. HKT) – at Citigate Dewe Rogerson, 8th Floor, Holborn Gate, 26 Southampton Buildings, London WC2A 1AN, UK. Investors may participate in the call at +44 20 3003 2666 (800 900 476 toll free in Hong Kong), or access a live video webcast of the call via Chi-Med’s website at event-information/ . U.S. Conference Call Scheduled Today at 9:00 a.m. EDT – to participate in the call from the U.S., please dial 1 866 966 5335. Additional dial-in numbers are also available at Chi-Med’s website . For both calls please use conference ID “ Chi-Med .” Operating HIGHLIGHTS The points below summarize some of Chi-Med’s operating highlights so far this year. For more details, please refer to “Operations Review” below. SURUFATINIB (HMPL-012 or sulfatinib) – angio-immuno kinase inhibitor of VEGFR 1/2/3, fibroblast growth factor receptor (“FGFR”) 1, and colony stimulating factor-1 receptor (“CSF-1R”): Positive China Phase III in non-pancreatic NET: An interim analysis in June 2019 confirmed that the Phase III non-pancreatic NET (SANET-ep) study met its primary endpoint of progression-free survival (“PFS”). As a result, the IDMC recommended the study be un-blinded, a year ahead of schedule, and preparations are now underway for an NDA submission in late 2019 for this indication in China; Initiated China Phase II/III in biliary tract cancer (“BTC”): Based on preliminary Phase Ib/IIa data, we initiated a Phase IIb/III registration study in BTC in China in March 2019; and Initiated PD-1 combination development: Received China IND clearance during early 2019 and initiated a Phase I safety run-in study in China of surufatinib plus Tuoyi ® , an approved PD-1 monoclonal antibody from Shanghai Junshi Biosciences Co. Ltd. (“Junshi”). FRUQUINTINIB – highly selective tyrosine kinase inhibitor (“TKI”) of VEGFR 1/2/3 – potential best-in-class in terms of both efficacy and safety: · Early progress on Elunate ® (fruquintinib capsules) in third-line CRC in China: o $11.4 million (RMB77.1 million) in sales during H1 2019: In-market sales of Elunate ® to third-parties, as provided by Lilly, in the first full six-month period since its November 25, 2018 launch; o Progress in reimbursement discussion: Elunate ® was included in the Shanghai provincial reimbursement drug list (“RDL”) in June 2019. Discussions now in-progress for potential inclusion in the China NRDL at the next update in early Q4 2019. · Cleared Phase III interim analysis in second-line gastric cancer: In April 2019, we conducted an interim analysis of the FRUTIGA study in China for futility. The analysis evaluated PFS and overall survival (“OS”) trends after six months of therapy for the first 100 patients in the study. The IDMC recommended to continue the study without changes; and Initiated PD-1 combination development: Received China IND clearance in early 2019 and initiated a Phase I study of fruquintinib plus Tyvyt ® , an approved PD-1 monoclonal antibody from Innovent Biologics (Suzhou) Co. Ltd. (“Innovent”). Phase I development of fruquintinib plus genolimzumab, a PD-1 monoclonal antibody under development by Genor Biopharma Co. Ltd. (“Genor”) is also now underway. SAVOLITINIB – potential first-in-class selective MET inhibitor in late-stage clinical development: · Reached enrollment goal in Phase II registration study – MET Exon 14 deletion NSCLC: Encouraging interim data, for 31 evaluable patients, for the China Phase II registration study in MET Exon 14 deletion NSCLC were presented during the 2019 American Association for Cancer Research (“AACR”) Annual Meeting. We have now reached our enrollment goal for this Phase II registration study, and subject to clinical outcome, with potential to be our first NDA submission for savolitinib in early 2020; · AstraZeneca collaboration, leading global position in EGFR-TKI resistant NSCLC: o 56% objective response rate (“ORR”) and 7.1 months’ median duration of response – in patients with acquired resistance to Iressa ® or Tarceva ® driven by MET amplification: Preliminary TATTON Phase Ib/IIa data for the savolitinib/Tagrisso ® combination regimen were presented at the 2019 AACR Annual Meeting for a total of 43 evaluable patients who were T790M- and had not previously received a third-generation EGFR inhibitor; o 31% ORR and 9.7 months’ median duration of response – in patients with acquired resistance to Tagrisso ® driven by MET amplification: Preliminary TATTON Phase Ib/IIa data for the savolitinib/Tagrisso ® combination regimen were also presented at the 2019 AACR Annual Meeting for a total of 39 evaluable patients who had reported disease progression after receiving a third-generation EGFR inhibitor. The SAVANNAH Phase IIb registration intent study, which is being conducted in North and South America, Europe and Asia in this target patient population, dosed its first patient in early 2019; · Emerging signal for savolitinib/Imfinzi ® (PD-L1) combination in renal cell carcinoma (“RCC”): Interim results for the papillary RCC (“PRCC”) cohort of the CALYPSO Phase II study were presented at the 2019 American Society of Clinical Oncology Genitourinary Symposium (“ASCO GU”) reporting a 27% ORR for all 41 patients and a 32% ORR for the 28 previously untreated patients. The combination was tolerable and associated with durable responses in PRCC. Further progress in early/proof-of-concept clinical trials and discovery, including: · HMPL-523 – potential first-in-class selective Syk inhibitor: A Phase Ib dose expansion study in both China and Australia accelerated enrollment in H1 2019 in multiple sub-types of non-Hodgkin’s lymphoma (“NHL”). We intend to use Phase Ib data to guide registration strategy in China during late 2019; and multiple U.S. / Europe sites are also now open for a Phase I/Ib study with patient screening underway. · HMPL-689 – potential best-in-class selective PI3Kδ inhibitor: A recommended dose for Phase II study has been selected based on the China Phase I study; U.S. / Europe IND applications cleared; and IND submission in China for HMPL-306: A novel selective small molecule TKI of isocitrate dehydrogenase (“IDH”) 1/2, discovered in-house with IND submitted H1 2019. Major organizational expansion, including: · Expansion of international clinical and regulatory operations: accelerated expansion of New Jersey team to support development of multiple un-partnered compounds outside of Asia; and · Establishment of China oncology commercial organization: currently numbering about 60 commercial staff, primarily focused on medical affairs and preparation for potential surufatinib launch in late 2020. POTENTIAL UPCOMING KEY EVENTS China – H2 2019 Global – H2 2019 1. Savolitinib – Registration study completion – MET Exon 14 deletion NSCLC (occurred July); 1. HMPL-523 (Syk) – Phase I – Initiate U.S. / E.U. Phase I/Ib in indolent NHL; 2. Surufatinib – Phase III data (SANET-ep) –presentation at scientific conference; 2. HMPL-689 (PI3Kδ) – Phase I – Initiate U.S. / E.U. Phase I/Ib in indolent NHL; 3. Surufatinib – NDA submission – in non-pancreatic NET; 3. Savolitinib – Phase II data (VIKTORY) – gastric cancer data (patient tumor molecular profiling). 4. Fruquintinib – Phase III data (FALUCA) – submit for presentation in NSCLC at conference; 5. Fruquintinib – Reimbursement – possible Elunate ® inclusion in China NRDL in Q4 2019. China – H1 2020 Global – H1 2020 6. Fruquintinib – Phase III interim analysis (FRUTIGA) – 2 nd interim in gastric cancer; 4. Surufatinib – Phase II/III start – initiate U.S. / E.U. study in pancreatic NET; 7. Surufatinib – Phase III interim analysis (SANET-p) – planned final interim analysis; 5. Fruquintinib – Phase II/III start – initiate U.S. / E.U. Phase II/III study in metastatic CRC; 8. Savolitinib – NDA submission – in MET Exon 14 deletion NSCLC; 6. Savolitinib – Phase II data (CALYPSO) – Imfinzi ® (PD-L1) combo in RCC; 9. Surufatinib – Phase Ib/II data – submit for presentation of BTC at conference; 7. Savolitinib – Phase II registration study (SAVANNAH) interim analysis – in NSCLC; 10. HMPL-523 – Phase II study start – potential registration study indolent NHL. FINANCIAL GUIDANCE We are providing the following updated Financial Guidance for the year ending December 31, 2019. Our updated guidance takes into account the weakening of the RMB, which was down 6% against the U.S. dollar during H1 2019 (using the average exchange rate for the period) relative to the same period last year due to global macroeconomic factors. We expect this trend to continue through the balance of 2019, and this depreciation of the RMB has the effect of reducing our R&D expenses in China in U.S. dollar terms. In addition, we have both expanded and extended existing studies of surufatinib and fruquintinib in the U.S. ahead of upcoming regulatory authority end of Phase II meetings. This will move certain start-up costs of our global Phase II/III registration studies on surufatinib and fruquintinib into 2020. 2019 Previous Guidance 2019 Current Guidance Adjustments Adjusted R&D Expenses $(160) – (200) million $(130) – (170) million $(30) million Adjusted Group Net Cash Flows excluding financing activities $(120) – (150) million $(90) – (120) million $(30) million Use of Non-GAAP Financial Measures – References in this announcement to adjusted R&D expenses, adjusted Group net cash flows and adjusted Group net cash flows excluding financing activities and financial measures reported at CER are based on non-GAAP financial measures. Please see the “Use of Non-GAAP Financial Measures and Reconciliation” below for further information relevant to the interpretation of these financial measures and reconciliations of these financial measures to the most comparable GAAP measures. About Chi-Med Chi-Med (AIM/Nasdaq: HCM) is an innovative biopharmaceutical company which researches, develops, manufactures and markets pharmaceutical products. Its Innovation Platform, Hutchison MediPharma, has about 440 scientists and staff focusing on discovering, developing and commercializing targeted therapeutics and immunotherapies in oncology and autoimmune diseases. It has a portfolio of eight cancer drug candidates currently in clinical studies around the world. Chi-Med’s Commercial Platform manufactures, markets, and distributes prescription drugs and consumer health products, covering an extensive network of hospitals across China. Chi-Med is headquartered in Hong Kong and is dual-listed on the AIM market of the London Stock Exchange and the Nasdaq Global Select Market. For more information, please visit: . CONTACTS Investor Enquiries Mark Lee, Senior Vice President +852 2121 8200 Annie Cheng, Vice President +1 (973) 567 3786 David Dible, Citigate Dewe Rogerson +44 7967 566 919 (Mobile) david.dible@ citigatedewerogerson.com Xuan Yang, Solebury Trout +1 (415) 971 9412 (Mobile) xyang@troutgroup.com Media Enquiries UK & Europe – Anthony Carlisle, Citigate Dewe Rogerson +44 7973 611 888 (Mobile) anthony.carlisle@ cdrconsultancy.co.uk Americas – Brad Miles, Solebury Trout +1 (917) 570 7340 (Mobile) bmiles@troutgroup.com Hong Kong & Asia ex-China – Joseph Chi Lo, Brunswick +852 9850 5033 (Mobile) jlo@brunswickgroup.com – Zhou Yi, Brunswick +852 9783 6894 (Mobile) yzhou@brunswickgroup.com Mainland China – Sam Shen, Edelman +86 136 7179 1029 (Mobile) sam.shen@edelman.com Nominated Advisor Richard Gray / Atholl Tweedie, Panmure Gordon (UK) Limited +44 (20) 7886 2500 References Unless the context requires otherwise, references in this announcement to the “Group,” the “Company,” “Chi-Med,” “Chi-Med Group,” “we,” “us,” and “our,” mean Hutchison China MediTech Limited and its consolidated subsidiaries and joint ventures unless otherwise stated or indicated by context. Past Performance and Forward-Looking Statements The performance and results of operations of the Group contained within this announcement are historical in nature, and past performance is no guarantee of future results of the Group. This announcement contains forward-looking statements within the meaning of the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by words like “will,” “expects,” “anticipates,” “future,” “intends,” “plans,” “believes,” “estimates,” “pipeline,” “could,” “potential,” “believe,” “first-in-class,” “best-in-class,” “designed to,” “objective,” “guidance,” “pursue,” or similar terms, or by express or implied discussions regarding potential drug candidates, potential indications for drug candidates, a potential SEHK listing and concurrent global offering of our securities or by discussions of strategy, plans, expectations or intentions. You should not place undue reliance on these statements. Such forward-looking statements are based on the current beliefs and expectations of management regarding future events, and are subject to significant known and unknown risks and uncertainties. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those set forth in the forward-looking statements. There can be no guarantee that any of our drug candidates will be approved for sale in any market, or that any approvals which are obtained will be obtained at any particular time, or that any such drug candidates will achieve any particular revenue or net income levels. In particular, management’s expectations could be affected by, among other things: unexpected regulatory actions or delays or government regulation generally; the uncertainties inherent in research and development, including the inability to me et our key study assumptions regarding enrollment rates, timing and availability of subjects meeting a study’s inclusion and exclusion criteria and funding requirements, changes to clinical protocols, unexpected adverse events or safety, quality or manufacturing issues; the inability of a drug candidate to meet the primary or secondary endpoint of a study; the inability of a drug candidate to obtain regulatory approval in different jurisdictions or gain commercial acceptance after obtaining regulatory approval; global trends toward health care cost containment, including ongoing pricing pressures; uncertainties regarding actual or potential legal proceedings, including, among others, actual or potential product liability litigation, litigation and investigations regarding sales and marketing practices, intellectual property disputes, and government investigations generally; and general economic and industry conditions, including uncertainties regarding the effects of the persistently weak economic and financial environment in many countries and uncertainties regarding future global exchange rates. For further discussion of these and other risks, see Chi-Med’s filings with the U.S. Securities and Exchange Commission and on AIM. Chi-Med is providing the information in this announcement as of this date and does not undertake any obligation to update any forward-looking statements as a result of new information, future events or otherwise. In addition, this announcement contains statistical data and estimates that Chi-Med obtained from industry publications and reports generated by third-party market research firms . Although Chi-Med believes that the publications, reports and surveys are reliable, Chi-Med has not independently verified the data and cannot guarantee the accuracy or completeness of such data. You are cautioned not to give undue weight to this data. Such data involves risks and uncertainties and are subject to change based on various factors, including those discussed above. Inside Information This announcement contains inside information for the purposes of Article 7 of Regulation (EU) No 596/2014. Ends

CBT’s c-Met inhibitor and anti-PD1 antibody to be evaluated in combination with Bossan’s EGFR inhibitor CBT’s c-Met inhibitor and anti-PD1 antibody to be evaluated in combination with Bossan’s EGFR inhibitor Pleasanton, CA, and Hangzhou, China, 26 November 2018 — CBT Pharmaceuticals (CBT) and Zhejiang Bossan Pharmaceutical Co., Ltd (Bossan) today announced that they have entered into a clinical collaboration and license agreement to develop their respective assets in combination with each another. The license agreement grants CBT exclusive, worldwide rights outside of Greater China to develop and commercialize ES-072, Bossan’s novel epidermal growth factor receptor (EGFR) inhibitor, in combination with CBT’s proprietary c-Met inhibitor (CBT-101) and anti-PD1 antibody (CBT-501). “CBT and Bossan share the desire to pool our respective development compounds on an exclusive, worldwide basis to develop safe and efficacious regimens that may lead to approval for the treatment of a variety of cancers,” said Guo-Liang Yu, PhD, CBT Global Chief Executive Officer and Venture Partner, OrbiMed. “As demonstrated by our commitment to evaluate combination therapy with the recent announcement of our APOLLO program, we continue to investigate our assets in combination with other plausible agents with sound mechanistic and scientific rationale, potentially yielding promising results in the clinic.” “Bossan is committed to reinforcing the foundation of lifesaving breakthroughs with new ideas. CBT’s assets have shown promising preclinical and early stage clinical data, and we believe that the synergy of our combined assets may lead to improved outcomes for solid tumor cancer patients,” added Bossan Chief Executive Officer, Dr. Hongguang Xia. CBT and Bossan intend to jointly develop a collaboration product and conduct joint clinical trials of CBT’s c-Met inhibitor (CBT-101), and/or anti-PD1 antibody (CBT-501), in combination with Bossan’s EGFR inhibitor (ES-072). Under the terms of the agreement, CBT will be responsible for conducting clinical trials globally outside of Greater China. Both a Joint Steering Committee and Joint Clinical Development Subcommittee will be formed to oversee and coordinate research, development, manufacturing, regulatory and commercial activities. About ES-072 ES-072 is a covalent, irreversible, mutant-selective EGFR inhibitor that has nanomolar inhibitory potency against EGFR (L858R, ex19del) and EGFR T790M. Pre-clinical data suggests that ES-072 is able to cross the blood brain barrier. ES-072 is currently in an ongoing Phase 1 clinical trial for non-small cell lung cancer (NSCLC) patients with mutant EGFR in China. About CBT-101 CBT-101 is a novel, small molecule drug that targets the epithelial to mesenchymal transition (EMT) pathway that is dysregulated in several tumors. It is a specific inhibitor of the c-Met receptor. CBT-101 has demonstrated tumor inhibitory effect in a variety of human primary c-Met amplified gastric, hepatic, pancreatic and lung cancer xenograft animal models with c-Met fusions, mutations or amplifications. In China, CBT-101 is referred to as PLB1001 where it is being developed by CBT’s partner Beijing Pearl Biotechnology Co. Ltd. Visit clinicaltrials.gov for additional information on the ongoing clinical trials: Combination NCT03655613 ; Single Agent NCT03175224 , NCT02896231 , and NCT02978261 . About CBT-501 CBT-501 is a novel IgG4 humanized monoclonal antibody against the Programmable Death-1 (PD-1) membrane receptor on immune cells. It has a comparable efficacy pro in vitro and in vivo studies to the marketed anti-PD-1 antibodies, nivolumab and pembrolizumab, and has a favorable pro very low antibody-dependent cell-mediated cytotoxicity (ADCC) and complement dependent cytotoxicity (CDC) activity. In China, CBT-501 is referred to as GB226 where it is being developed by CBT partner Genor BioPharma Co. Ltd. Visit clinicaltrials.gov for additional information on the ongoing clinical trials: NCT03053466 , NCT03374007 , NCT03502629 , NCT03623581 , and NCT03639181 . About Zhejiang Bossan Pharmaceutical Co., Ltd Bossan Pharmaceutical Co. is a company focusing on the development of targeted, small molecule therapeutics against tumors. Bossan’s pipeline includes one clinical stage and multiple preclinical stage drug candidates. Bossan is interested in combining targeted drugs with cancer immunotherapies to create more effective treatments for specific cancer patients. For more information, please visit About CBT Pharmaceuticals, Inc. CBT Pharmaceuticals, Inc. is an innovative biopharmaceutical company committed to becoming a global leader in the discovery and development of oncology combination therapies that harness the immune system and target specific molecular pathways to tame cancer. The company’s existing pipeline consists of five development-stage assets including three novel, humanized monoclonal antibodies that restore the body’s immune system to recognize and kill cancer cells, and two targeted therapies against uncontrolled growth signaling pathways. For more information, please contact us and follow us on Twitter @CBTpharma . Contact: Remy Bernarda Corporate Communications (415) 203-6386 Remy.Bernarda@cbtpharma.com Zhejiang Bossan Pharmaceutical Co., Ltd Contact: Zhen Tian Corporate Communications (86)-571-88575573 zhen.tian@bosmedic.com